Anelixis Therapeutics is a biotechnology company developing therapies for patients with neurodegenerative and autoimmune diseases. It is engaged in the development of antibodies blocking CD40L activity for autoimmunity, organ and cellular transplantation, and amyotrophic lateral sclerosis.